Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis

Harvey Sarnat1, Laura Flores-Sarnat, Peter Crino

  • 1University of Calgary and Alberta Children's Hospital Calgary, Alberta, Canada. harvey.sarnat@albertahealthservices.ca

Folia Neuropathologica
|January 16, 2013
PubMed
Abstract

Insights

Hemimegalencephaly (HME) involves abnormal brain growth. This study found abnormal tau protein and mTOR pathway activation in HME, suggesting early microtubule defects and potential lipid metabolism issues.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Cellular Biology

Background:

  • Hemimegalencephaly (HME) is a rare congenital disorder characterized by the malformation of one cerebral hemisphere.
  • It represents a hamartomatous overgrowth, indicating a disruption in cellular growth and lineage during early development.

Purpose of the Study:

  • To investigate potential early disturbances in microtubule assembly or function in Hemimegalencephaly (HME).
  • To explore the role of the mTOR pathway and tau protein phosphorylation in HME pathogenesis.

Main Methods:

  • Analysis of brain tissue from three male infants with HME who underwent resections for refractory epilepsy.
  • Assessment of phosphorylated tau protein, transmission electron microscopy (EM), and mTOR pathway activation markers (P-4E-BP1, P-S6).
  • Examination of lipid accumulation in neurons and glial cells.

Main Results:

  • HME brain tissue showed cytoarchitectural abnormalities and intense tau immunoreactivity.
  • Evidence of mTOR pathway hyperactivation was observed, indicated by P-4E-BP1 and P-S6 immunoreactivity.
  • Transmission electron microscopy revealed abundant lipid accumulation in neurons and astrocytic end-feet, suggesting lipidosis.

Conclusions:

  • The findings suggest that Hemimegalencephaly (HME) pathogenesis may involve early microtubule defects, potentially linked to the AKT3 gene, and mTOR hyperactivation.
  • Lipidosis in neurons and glia indicates a metabolic impairment that may be related to the observed tauopathy.
  • Perinatal treatment with everolimus is proposed as a potential therapeutic strategy for HME.

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...